Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1741-7015
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial ; volume:17 ; number:1 ; day:9 ; month:1 ; year:2019 ; pages:1-12 ; date:12.2019
BMC medicine ; 17, Heft 1 (9.1.2019), 1-12, 12.2019
- Creator
-
Gavilá, Joaquín
Oliveira, Mafalda
Pascual, Tomás
Perez-Garcia, Jose
Gonzàlez, Xavier
Canes, Jordi
Paré, Laia
Calvo, Isabel
Ciruelos, Eva
Muñoz, Montserrat
Virizuela, Juan A.
Ruiz, Isabel
Andrés, Raquel
Perelló, Antonia
Martínez, Jerónimo
Morales, Serafín
Marín-Aguilera, Mercedes
Martínez, Débora
Quero, Juan C.
Llombart-Cussac, Antonio
Prat, Aleix
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12916-018-1233-1
- URN
-
urn:nbn:de:101:1-2019021203050663964298
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gavilá, Joaquín
- Oliveira, Mafalda
- Pascual, Tomás
- Perez-Garcia, Jose
- Gonzàlez, Xavier
- Canes, Jordi
- Paré, Laia
- Calvo, Isabel
- Ciruelos, Eva
- Muñoz, Montserrat
- Virizuela, Juan A.
- Ruiz, Isabel
- Andrés, Raquel
- Perelló, Antonia
- Martínez, Jerónimo
- Morales, Serafín
- Marín-Aguilera, Mercedes
- Martínez, Débora
- Quero, Juan C.
- Llombart-Cussac, Antonio
- Prat, Aleix
- SpringerLink (Online service)
Other Objects (12)
Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer
Kupffer cells determine intrahepatic traffic of PEGylated liposomal doxorubicin
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)
A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Outcomes of AIDS-associated Kaposi sarcoma in Mozambique after treatment with pegylated liposomal doxorubicin
Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer
Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice
A multifunctional PEGylated liposomal-encapsulated sunitinib enhancing autophagy, immunomodulation, and safety in renal cell carcinoma
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer
Kupffer cells determine intrahepatic traffic of PEGylated liposomal doxorubicin
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)
A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Outcomes of AIDS-associated Kaposi sarcoma in Mozambique after treatment with pegylated liposomal doxorubicin
Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer
Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice
A multifunctional PEGylated liposomal-encapsulated sunitinib enhancing autophagy, immunomodulation, and safety in renal cell carcinoma
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer
Kupffer cells determine intrahepatic traffic of PEGylated liposomal doxorubicin
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)
A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Outcomes of AIDS-associated Kaposi sarcoma in Mozambique after treatment with pegylated liposomal doxorubicin
Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer
Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice
A multifunctional PEGylated liposomal-encapsulated sunitinib enhancing autophagy, immunomodulation, and safety in renal cell carcinoma